Biblio

Author Title Type [ Year(Asc)]
Filters: Author is de Moerloose, Barbara  [Clear All Filters]
2024
Tierens A, Arad-Cohen N, Cheuk D, de Moerloose B, Navarro JMaria Fern, Hasle H, Jahnukainen K, Juul-Dam KLøvvik, Kaspers G, Kovalova Z, et al. Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease. J Clin Oncol. 2024:JCO2301841.
van Weelderen RElise, Harrison CJ, Klein K, Jiang Y, Abrahamsson J, Alonzo T, Aplenc R, Arad-Cohen N, Bart-Delabesse E, Buldini B, et al. Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia. Blood Adv. 2024.
2023
Vanhooren J, Dobbelaere R, Derpoorter C, Deneweth L, Van Camp L, Uyttebroeck A, de Moerloose B, Lammens T. CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them. Hemasphere. 2023;7(9):e937.
Karlsson L, Cheuk D, de Moerloose B, Hasle H, Jahnukainen K, Juul-Dam KLøvvik, Kaspers G, Kovalova Z, Lausen B, Nyström UNorén, et al. Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia. Br J Haematol. 2023.
Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, Kiani A, Krumbholz M, Luesink M, Naumann-Bartsch N, et al. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia. 2023.
van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, de Moerloose B, Dworzak MN, et al. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol. 2023:JCO2202120.
Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, de Moerloose B, Schmiegelow K, Burns MA, et al. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials. J Clin Oncol. 2023:JCO2300088.
Erlacher M, Andresen F, Sukova M, Stary J, de Moerloose B, Bosch Jvan der We, Dworzak M, Seidel MG, Polychronopoulou S, Beier R, et al. Spontaneous remission and loss of monosomy 7: a window of opportunity for young children with SAMD9L syndrome. Haematologica. 2023.
2022
Attarbaschi A, Möricke A, Harrison CJ, Mann G, Baruchel A, de Moerloose B, Conter V, Devidas M, Elitzur S, Escherich G, et al. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/ Rearrangements in a Modern Therapy Era: A Retrospective International Study. J Clin Oncol. 2022:JCO2201297.
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, de Moerloose B, Qayed M, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2022:JCO2200642.
2021
Sahoo SS, Pastor VB, Goodings C, Voss RK, Kozyra EJ, Szvetnik A, Noellke P, Dworzak M, Stary J, Locatelli F, et al. Publisher Correction: Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nat Med. 2021.
2019
Laetsch TW, Myers GDouglas, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, de Moerloose B, Davis KL, Nemecek E, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019.
Doz F, Locatelli F, Baruchel A, Blin N, de Moerloose B, Frappaz D, Dworzak M, Fischer M, Stary J, Fuertig R, et al. Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatr Blood Cancer. 2019:e27900.
2018
Polonini H, da Silva SLoures, Brandão MAntônio F, Bauters T, de Moerloose B, Ferreira Ade Oliveir. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycho. Int J Pharm Compd. 2018;22(6):516-526.
2015
Wlodarski MW, Hirabayashi S, Pastor V, Stary J, Hasle H, Masetti R, Dworzak M, Schmugge M, van den Heuvel-Eibrink M, Ussowicz M, et al. Prevalence, clinical characteristics and prognosis of GATA2-related myelodysplastic syndromes (MDS) in children and adolescents. Blood. 2015.
2014
Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, Rondou P, Vandenberghe P, Delabesse E, Lammens T, et al. The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood. 2014.
2013
Yoshimi A, van den Heuvel-Eibrink MM, Baumann I, Schwarz S, Simonitsch-Klupp I, de Paepe P, Campr V, Kerndrup GBirk, Sullivan MO', Devito R, et al. Comparison of horse and rabbit anti-thymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica. 2013.